Fenwick & West represented Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, in its follow-on public offering raising gross proceeds, before underwriting discounts and commissions and estimated offering expenses, of $111 million. On August 11, 2015, Dermira closed the follow-on public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stocks at a price to the public of $21.50 per share.
Leerink Partners LLC, Cowen and Company and Guggenheim Securities acted as joint book-running managers for the offering. Needham & Company acted as co-manager.
The Fenwick transaction team included corporate attorneys Doug Cogen, Michael Brown, Robert Freedman, Katherine Duncan and Jennifer Hitchcock.